Standard Standard

Refractory depression - mechanisms and efficacy of radically open dialectical behaviour therapy (RefraMED): findings of a randomised trial on benefits and harms. / Lynch, Thomas R.; Hempel, Roelie J; Whalley, Ben et al.
In: British Journal of Psychiatry, Vol. 216, No. 4, 04.2020, p. 204-212.

Research output: Contribution to journalArticlepeer-review

HarvardHarvard

Lynch, TR, Hempel, RJ, Whalley, B, Byford, S, Chamba, R, Clarke, P, Clarke, S, Kingdon, DG, O'Mahen, H, Remington, B, Rushbrook, SC, Shearer, J, Stanton, M, Swales, M, Watkins, A & Russell, IT 2020, 'Refractory depression - mechanisms and efficacy of radically open dialectical behaviour therapy (RefraMED): findings of a randomised trial on benefits and harms', British Journal of Psychiatry, vol. 216, no. 4, pp. 204-212. https://doi.org/10.1192/bjp.2019.53

APA

Lynch, T. R., Hempel, R. J., Whalley, B., Byford, S., Chamba, R., Clarke, P., Clarke, S., Kingdon, D. G., O'Mahen, H., Remington, B., Rushbrook, S. C., Shearer, J., Stanton, M., Swales, M., Watkins, A., & Russell, I. T. (2020). Refractory depression - mechanisms and efficacy of radically open dialectical behaviour therapy (RefraMED): findings of a randomised trial on benefits and harms. British Journal of Psychiatry, 216(4), 204-212. https://doi.org/10.1192/bjp.2019.53

CBE

Lynch TR, Hempel RJ, Whalley B, Byford S, Chamba R, Clarke P, Clarke S, Kingdon DG, O'Mahen H, Remington B, et al. 2020. Refractory depression - mechanisms and efficacy of radically open dialectical behaviour therapy (RefraMED): findings of a randomised trial on benefits and harms. British Journal of Psychiatry. 216(4):204-212. https://doi.org/10.1192/bjp.2019.53

MLA

VancouverVancouver

Lynch TR, Hempel RJ, Whalley B, Byford S, Chamba R, Clarke P et al. Refractory depression - mechanisms and efficacy of radically open dialectical behaviour therapy (RefraMED): findings of a randomised trial on benefits and harms. British Journal of Psychiatry. 2020 Apr;216(4):204-212. Epub 2019 Jul 18. doi: 10.1192/bjp.2019.53

Author

Lynch, Thomas R. ; Hempel, Roelie J ; Whalley, Ben et al. / Refractory depression - mechanisms and efficacy of radically open dialectical behaviour therapy (RefraMED) : findings of a randomised trial on benefits and harms. In: British Journal of Psychiatry. 2020 ; Vol. 216, No. 4. pp. 204-212.

RIS

TY - JOUR

T1 - Refractory depression - mechanisms and efficacy of radically open dialectical behaviour therapy (RefraMED)

T2 - findings of a randomised trial on benefits and harms

AU - Lynch, Thomas R.

AU - Hempel, Roelie J

AU - Whalley, Ben

AU - Byford, Sarah

AU - Chamba, Rampaul

AU - Clarke, Paul

AU - Clarke, Susan

AU - Kingdon, David G

AU - O'Mahen, Heather

AU - Remington, Bob

AU - Rushbrook, Sophie C

AU - Shearer, James

AU - Stanton, Maggie

AU - Swales, Michaela

AU - Watkins, Alan

AU - Russell, Ian T.

N1 - This peer-reviewed grant 09/150/12 was funded by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership. The EME Programme is funded by the MRC and NIHR, with contributions from the CSO in Scotland and Health and Care Research Wales and the HSC R&D Division, Public Health Agency in Northern Ireland

PY - 2020/4

Y1 - 2020/4

N2 - BACKGROUND: Individuals with depression often do not respond to medication or psychotherapy. Radically open dialectical behaviour therapy (RO DBT) is a new treatment targeting overcontrolled personality, common in refractory depression.AIMS: To compare RO DBT plus treatment as usual (TAU) for refractory depression with TAU alone (trial registration: ISRCTN 85784627).METHOD: RO DBT comprised 29 therapy sessions and 27 skills classes over 6 months. Our completed randomised trial evaluated RO DBT for refractory depression over 18 months in three British secondary care centres. Of 250 adult participants, we randomised 162 (65%) to RO DBT. The primary outcome was the Hamilton Rating Scale for Depression (HRSD), assessed masked and analysed by treatment allocated.RESULTS: After 7 months, immediately following therapy, RO DBT had significantly reduced depressive symptoms by 5.40 points on the HRSD relative to TAU (95% CI 0.94-9.85). After 12 months (primary end-point), the difference of 2.15 points on the HRSD in favour of RO DBT was not significant (95% CI -2.28 to 6.59); nor was that of 1.69 points on the HRSD at 18 months (95% CI -2.84 to 6.22). Throughout RO DBT participants reported significantly better psychological flexibility and emotional coping than controls. However, they reported eight possible serious adverse reactions compared with none in the control group.CONCLUSIONS: The RO DBT group reported significantly lower HRSD scores than the control group after 7 months, but not thereafter. The imbalance in serious adverse reactions was probably because of the controls' limited opportunities to report these.

AB - BACKGROUND: Individuals with depression often do not respond to medication or psychotherapy. Radically open dialectical behaviour therapy (RO DBT) is a new treatment targeting overcontrolled personality, common in refractory depression.AIMS: To compare RO DBT plus treatment as usual (TAU) for refractory depression with TAU alone (trial registration: ISRCTN 85784627).METHOD: RO DBT comprised 29 therapy sessions and 27 skills classes over 6 months. Our completed randomised trial evaluated RO DBT for refractory depression over 18 months in three British secondary care centres. Of 250 adult participants, we randomised 162 (65%) to RO DBT. The primary outcome was the Hamilton Rating Scale for Depression (HRSD), assessed masked and analysed by treatment allocated.RESULTS: After 7 months, immediately following therapy, RO DBT had significantly reduced depressive symptoms by 5.40 points on the HRSD relative to TAU (95% CI 0.94-9.85). After 12 months (primary end-point), the difference of 2.15 points on the HRSD in favour of RO DBT was not significant (95% CI -2.28 to 6.59); nor was that of 1.69 points on the HRSD at 18 months (95% CI -2.84 to 6.22). Throughout RO DBT participants reported significantly better psychological flexibility and emotional coping than controls. However, they reported eight possible serious adverse reactions compared with none in the control group.CONCLUSIONS: The RO DBT group reported significantly lower HRSD scores than the control group after 7 months, but not thereafter. The imbalance in serious adverse reactions was probably because of the controls' limited opportunities to report these.

U2 - 10.1192/bjp.2019.53

DO - 10.1192/bjp.2019.53

M3 - Article

C2 - 31317843

VL - 216

SP - 204

EP - 212

JO - British Journal of Psychiatry

JF - British Journal of Psychiatry

SN - 0007-1250

IS - 4

ER -